Molecular framework-based stratification schemes have been developed and introduced into clinical practice for a number of CNS tumors; examples include IDH1/2 mutations and 1p/19q codeletions for gliomas and oligodendrogliomas [10]; KIAA1549-BRAF fusions, MYB/MYBL rearrangements, recurrent pathogenic mutations in BRAF and H3F3A for pediatric astrocytomas [11,12]; and four molecular groups with the account of MYC/MYCN amplification for medulloblastomas [13]. This evidence concerns the gene BRAF and astrocytoma (excluding glioblastoma).